NCI-sponsored Clinical Trial Research Specialist

摘要 NCI赞助的临床试验代表了UF Health进行的一些最优先的临床试验 癌症中心(UFHCC)。这些试验包括在我们中心就诊的患者以及那些 通过我们在整个佛罗里达州的学术研究联盟，提供对哪里的试验访问 病人是这样的。UFCC致力于通过牢固的合作伙伴关系成功地进行NCI赞助的临床试验 与国家临床试验网络(NCTN)通过儿童肿瘤学小组(COG)、NRG肿瘤学 以及实验治疗临床试验网络(ETCTN)。这一承诺体现在 多个级别，包括但不限于，优先安排研究人员参与NCI赞助的临床试验， 促进快速高效的激活，财政补贴试验费用，支持教职员工 作为内容专家/委员出席会议，主持COG统计和数据中心， 将对参与的期望纳入工资支持，并提供一种机制，使区域 社区肿瘤学实践，以获得试验。我在每个机构层面上的参与和努力都 从而提高了生产力、效率和影响力。其中包括我作为UFCC首任成员的领导能力 临床研究副主任(ADCR)、实验治疗组主任和主任 胃肠道肿瘤学项目。NCI赞助的临床试验的投资组合优先顺序、监督和登记情况如下 这是一个明显的体制优先事项。在NCI赞助的临床试验网络中，我也很活跃，并提供 通过行政领导产生影响。我担任GI委员会的NRG肿瘤学联合主席， 结直肠癌小组委员会成员，通讯委员会成员。我还担任 UFCC机构PI为ETCTN和耶鲁老会员。我个人参与了NCI的同行审查 在被批准之前对概念进行科学价值、影响和可行性评估的过程 审判。这些审查发生在NCI疾病特定工作组，具体地说，食道胃， 肝胆、胰腺、神经内分泌、结肠癌和直肠-肛门癌NCI特别工作组以及试验决赛 批准成为NCI胃肠指导委员会的有投票权的成员。通过这些职位和与 其他贡献，我积极和积极地影响了NCTN的当前和未来格局 和ETCTN计划，特别是GI肿瘤学试验组合。我的职业目标包括继续为 NCI通过领导力、新成员参与和试验支持的临床试验网络 开发/完成，同时通过扩大试验提高我的机构参与度 引导和扩展新一代有能力的、多样化的NCI临床研究人员，利用我的 领导力、经验、指导和赞助。

ABSTRACT NCI-sponsored clinical trials represent some of the highest priority clinical trials conducted by the UF Health Cancer Center (UFHCC). These trials include participation by patients seen at our center as well as those through our academic research consortium across the entire state of Florida to deliver trial access to where patients are. The UFHCC is committed to the success of NCI-sponsored clinical trials through robust partnerships with the National Clinical Trials Network (NCTN) through the Children's Oncology Group (COG), NRG Oncology as well as the Experimental Therapeutics Clinical Trial Network (ETCTN). This commitment is demonstrated at multiple levels including, but not limited to, prioritizing investigator participation in NCI-sponsored clinical trials, facilitating rapid and efficient activation, financially subsidizing the costs of trial conduct, supporting faculty to attend meetings serving as content experts/committee members, hosting the COG Statistical and Data Center, embedding expectations for participation into salary support, and providing a mechanism to allow regional community oncology practices to access trials. My involvement and effort at each of these institutional levels has resulted in improved productivity, efficiency, and impact. These include my leadership as the inaugural UFHCC Associate Director for Clinical Research (ADCR), Director of the Experimental Therapeutics Group, and Director of the GI Oncology Program. Portfolio priority, oversight and enrollments to the NCI-sponsored clinical trials are a demonstrated institutional priority. Within the NCI-sponsored clinical trial networks, I am also active and provide impact through administrative leadership. I serve as the NRG Oncology Co-Chair of the GI Committee, Chair of the Colorectal Cancer Subcommittee, and member of the Communications Committee. I also serve as the UFHCC institutional PI to the ETCTN and Yale LAO member. I am personally involved in the NCI peer-review process by which concepts are evaluated for scientific merit, impact, and feasibility prior to being approved as trials. These reviews occur in the NCI disease-specific Task Forces, specifically, the Esophagogastric, Hepatobiliary, Pancreatic, Neuroendocrine, Colon, and Rectal-Anal Cancer NCI Task Forces as well as trial final approval as a voting member of the NCI Gastrointestinal Steering Committee. Through these positions and with additional contributions, I have actively and positively influenced the current and future landscape of the NCTN and ETCTN programs, particularly the GI Oncology trial portfolio. My career goals include continued service to the NCI-sponsored clinical trial networks through leadership, new member engagement and trial development/completion while simultaneously increasing my institutional engagement through expanded trial conduct and expanding the next generation of capable and diverse NCI clinical investigators leveraging my leadership, experience, mentorship, and sponsorship.